{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:41:33Z","timestamp":1791895293765,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370786"],"award-info":[{"award-number":["82370786"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070878"],"award-info":[{"award-number":["82070878"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2020J011081"],"award-info":[{"award-number":["2020J011081"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2021J01381"],"award-info":[{"award-number":["2021J01381"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.eprac.2025.01.012","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T19:25:42Z","timestamp":1739388342000},"page":"640-649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: A\u00a0Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"31","author":[{"given":"Wenxin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5650-5281","authenticated-orcid":false,"given":"Junping","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2025.01.012_bib1","article-title":"Presentation of graves' orbitopathy within European group on graves' orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III)","author":"Schuh","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.eprac.2025.01.012_bib2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2025.01.012_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology, natural history, risk factors, and prevention of graves' orbitopathy","volume":"11","author":"Bartalena","year":"2020","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2025.01.012_bib4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev"},{"issue":"7","key":"10.1016\/j.eprac.2025.01.012_bib5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/13543784.2020.1772752","article-title":"Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy","volume":"29","author":"Slentz","year":"2020","journal-title":"Expet Opin Invest Drugs"},{"issue":"4","key":"10.1016\/j.eprac.2025.01.012_bib6","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.eprac.2025.01.012_bib7","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/BF03346732","article-title":"Dose of intravenous steroids and therapy outcome in Graves' orbitopathy","volume":"34","author":"Zang","year":"2011","journal-title":"J\u00a0Endocrinol Investig"},{"issue":"2","key":"10.1016\/j.eprac.2025.01.012_bib8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1530\/EJE-11-0779","article-title":"Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association","volume":"166","author":"Marcocci","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2025.01.012_bib9","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.01.012_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41433-018-0321-y","article-title":"Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis","volume":"33","author":"Douglas","year":"2019","journal-title":"Eye"},{"issue":"1","key":"10.1016\/j.eprac.2025.01.012_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13044-020-00086-7","article-title":"Teprotumumab: a disease modifying treatment for Graves' orbitopathy","volume":"13","author":"Ting","year":"2020","journal-title":"Thyroid Res"},{"issue":"18","key":"10.1016\/j.eprac.2025.01.012_bib12","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.01.012_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2025.01.012_bib14","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"Declaraci\u00f3n PRISMA 2020: una gu\u00eda actualizada para la publicaci\u00f3n de revisiones sistem\u00e1ticas","volume":"74","author":"Page","year":"2021","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.eprac.2025.01.012_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement","volume":"134","author":"Page","year":"2021","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.eprac.2025.01.012_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.eprac.2025.01.012_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2025.01.012_bib18","series-title":"Methods Guide for Effectiveness and Comparative Effectiveness Reviews","article-title":"Assessing the risk of bias of individual studies in systematic reviews of health care interventions","author":"Viswanathan","year":"2008"},{"issue":"1","key":"10.1016\/j.eprac.2025.01.012_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas","year":"2023","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2025.01.012_bib20","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and Re-treatment","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.eprac.2025.01.012_bib21","article-title":"Outcomes of patients with thyroid eye disease partially treated with teprotumumab","author":"Ho","year":"2022","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"6","key":"10.1016\/j.eprac.2025.01.012_bib22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/IOP.0000000000001959","article-title":"Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population","volume":"37","author":"Diniz","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"10.1016\/j.eprac.2025.01.012_bib23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4103\/tjo.tjo_30_22","article-title":"Effect of teprotumumab on intraocular pressure in thyroid-associated ophthalmopathy","volume":"12","author":"Adetunji","year":"2022","journal-title":"Taiwan J Ophthalmol"},{"issue":"6","key":"10.1016\/j.eprac.2025.01.012_bib24","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/bjophthalmol-2020-318314","article-title":"Improvement of asymmetric thyroid eye disease with teprotumumab","volume":"106","author":"Ugradar","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.eprac.2025.01.012_bib25","doi-asserted-by":"crossref","DOI":"10.1089\/thy.2023.0167","article-title":"Medical therapy in patients with moderate to severe, steroid-resistant, thyroid eye disease","author":"Toro-Tobon","year":"2023","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.eprac.2025.01.012_bib26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.beem.2011.10.002","article-title":"Role of insulin-like growth factor-1 (IGF-1)\u00a0pathway in the pathogenesis of Graves' orbitopathy","volume":"26","author":"Smith","year":"2012","journal-title":"Best Pract Res\u00a0Clin Endocrinol Metabol"},{"issue":"10","key":"10.1016\/j.eprac.2025.01.012_bib27","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1210\/en.2016-1304","article-title":"Pathogenic phenotype of adipogenesis and hyaluronan in orbital fibroblasts from female Graves' orbitopathy mouse model","volume":"157","author":"G\u00f6rtz","year":"2016","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.eprac.2025.01.012_bib28","doi-asserted-by":"crossref","first-page":"e1653","DOI":"10.1210\/clinem\/dgab824","article-title":"Inhibition of TSH\/IGF-1 receptor crosstalk by teprotumumab as a treatment modality of thyroid eye disease","volume":"107","author":"Krieger","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2025.01.012_bib29","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1210\/jc.2016-1315","article-title":"TSH\/IGF-1 receptor cross talk in Graves' ophthalmopathy pathogenesis","volume":"101","author":"Krieger","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2025.01.012_bib30","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0189","article-title":"Management of thyroid eye disease: a consensus statement by the American thyroid association and the European thyroid association","volume":"11","author":"Burch","year":"2022","journal-title":"Eur Thyroid J"},{"issue":"2","key":"10.1016\/j.eprac.2025.01.012_bib31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/IOP.0000000000002027","article-title":"Tocilizumab for the management of thyroid-associated orbitopathy","volume":"38","author":"Smith","year":"2022","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2025.01.012_bib32","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1210\/clinem\/dgac328","article-title":"Understanding pathogenesis intersects with effective treatment\u00a0for thyroid eye disease","volume":"107","author":"Smith","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.01.012_bib33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ajo.2019.07.021","article-title":"A\u00a0new era in the treatment of thyroid eye disease","volume":"208","author":"Patel","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.eprac.2025.01.012_bib34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/phar.2111","article-title":"Efficacy and safety of rituximab for the treatment of Graves' orbitopathy: a meta-analysis of randomized controlled trials","volume":"38","author":"Shen","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.eprac.2025.01.012_bib35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/bjophthalmol-2020-317806","article-title":"Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease","volume":"106","author":"Jain","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.eprac.2025.01.012_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.754386","article-title":"Precision medicine in Graves' disease and ophthalmopathy","volume":"12","author":"Elia","year":"2021","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.eprac.2025.01.012_bib37","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.01.012_bib38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ophtha.2023.08.001","article-title":"Frequency and patterns of hearing dysfunction in patients treated with teprotumumab","volume":"131","author":"Keen","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.eprac.2025.01.012_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","article-title":"Hearing dysfunction after treatment with teprotumumab for thyroid eye disease","volume":"240","author":"Sears","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.eprac.2025.01.012_bib40","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1097\/IOP.0000000000002355","article-title":"Reduction of teprotumumab-induced hearing loss with comparable efficacy using half-dose therapy","volume":"39","author":"Phansalkar","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"11","key":"10.1016\/j.eprac.2025.01.012_bib41","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1634\/theoncologist.2015-0519","article-title":"Hyperglycemia associated with\u00a0targeted oncologic treatment: mechanisms and management","volume":"21","author":"Goldman","year":"2016","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.eprac.2025.01.012_bib42","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.tem.2013.03.004","article-title":"The therapeutic potential of IGF-I in skeletal muscle repair","volume":"24","author":"Song","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.01.012_bib43","author":"Amgen"},{"issue":"2","key":"10.1016\/j.eprac.2025.01.012_bib44","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/IOP.0000000000002591","article-title":"Disease modulation versus modification: a call for revised outcome metrics in the treatment of thyroid eye disease","volume":"40","author":"North","year":"2024","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.eprac.2025.01.012_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1160936","article-title":"Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves' ophthalmopathy: a systematic review and meta-analysis","volume":"14","author":"Hu","year":"2023","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.eprac.2025.01.012_bib46","first-page":"1553","article-title":"Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease: a meta-analysis and matching-adjusted indirect comparison","volume":"2023","author":"Douglas","year":"2022","journal-title":"Int J Clin Pract"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25000448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25000448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:58:12Z","timestamp":1762549092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25000448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1530891X25000448"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.01.012","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: A\u00a0Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}